"Never doubt that a small group of thoughtful, committed citizens can change the world. Indeed, it is the only thing that ever has."

Margaret Mead
Cureus is now part of Springer Nature! Click here to read more about what this means for the Cureus community of readers, reviewers and authors.

Original article
peer-reviewed

Dimethyl Fumarate Ameliorates Paclitaxel-Induced Neuropathic Pain in Rats



Abstract

Background

Paclitaxel (PTX)-induced peripheral neuropathy (PIPN) is nonresponsive to the currently available analgesics. Previous studies have shown the role of oxidative stress and central sensitization in the development of peripheral neuropathy. Dimethyl fumarate (DMF) acts as a nuclear factor erythroid-2-related factor 2 (Nrf2) activator with neuroprotective benefits and is approved for use in multiple sclerosis.

Materials and methods

In the current research, we evaluated the efficacy of DMF on paclitaxel-induced peripheral neuropathy in rats. Every alternate day for one week, paclitaxel 2 mg/kg dose was injected to establish a rat model of PIPN. Animals were treated with 25 mg/kg and 50 mg/kg of DMF. All the animals were assessed for thermal hyperalgesia, cold allodynia, and mechanical allodynia once a week. The gene expression of Nrf2 and the levels of pro-inflammatory mediators (interleukin (IL)-6, tumor necrosis factor-alpha (TNF-α), and IL-1β) were quantified in the sciatic nerves of these rats. The levels of p38 mitogen-activated protein kinase (MAPK) and brain-derived neurotrophic factor (BDNF) were quantified in the dorsal horn of the spinal cord.

Results

DMF significantly attenuated paclitaxel-induced thermal hyperalgesia and cold/mechanical allodynia. A significant decrease in the levels of pro-inflammatory cytokines with the levels of p38 MAPK and BDNF was observed in the DMF-treated animals. DMF treatment significantly upregulated the gene expression of Nrf2 in the sciatic nerve.

Conclusion

These findings suggest that DMF prevented the development of PIPN in rats through the activation of Nrf2 and the inhibition of p38 MAPK and BDNF.

Introduction

Paclitaxel (PTX) is a plant alkaloid used as a chemotherapeutic agent in the treatment of breast, lung, and ovarian cancer. Unfortunately, paclitaxel causes a dose-limiting adverse effect termed peripheral neuropathy with the symptoms of pain, tingling, numbness, and sensitivity to cold in the stocking-glove areas [1]. Around 30%-40% of patients undergoing antineoplastic treatment experience these symptoms, which may persist for about 2-3 years [2,3]. Paclitaxel-induced peripheral neuropathy (PIPN) not only decreases the quality of life but also sometimes results in the cessation of chemotherapy when symptoms become extreme. Currently, available treatment provides minimal symptomatic relief and no or very little protection to peripheral nerves [4]. There have been multiple clinical and nonclinical studies, but none have come up with a breakthrough treatment for PIPN.

Evidence from various studies sheds light on oxidative stress as a particular component that contributes to the pathogenesis of peripheral neuropathy [5,6]. Several phytochemicals and drugs with reactive oxygen species (ROS)-scavenging properties have shown anti-neuropathic effects in multiple in vivo chemotherapy-induced peripheral neuropathy (CIPN) models [7]. In addition, some recent studies have shown the role of central sensitization in worsening neuropathic pain [8]. Nuclear factor erythroid-2-related factor 2 (Nrf2) acts as an essential modulator of in-house antioxidant defense [9]. It is a leucine zipper transcription factor that senses the change in redox activities and communicates with Kelch-like ECH-associated protein 1 inhibitory binding domain (KEAP 1) for antioxidant and anti-inflammatory responses. Nrf2 activation promotes a series of detoxification proteins through the antioxidant response element (ARE) [10]. Nrf2-ARE signaling cascade controls the production of multiple cytoprotective proteins, such as nucleotide adenosine diphosphate hydrogenase (NADPH), quinone oxidoreductase-1 (NQO1), glutathione (GSH) reduced, superoxide dismutase, and heme oxygenase-1 (HO-1) [11]. Furthermore, central sensitization leads to hypersensitivity to touch, heat, and cold. Spinal brain-derived neurotropic factor (BDNF) is one of the biomarkers for the central sensitization of pain. Previous studies show that the release of BDNF increases from microglial cells when there is peripheral nerve injury, which is mediated by adenosine triphosphate (ATP)-gated ionotropic purinoceptor, 2X4 (P2X4R) overexpression. This increase in expression parallels the increase in pain hypersensitivity [12]. This upregulation in P2X4Rs causes an increased influx of Ca+2, the activation of p38 mitogen-activated protein kinases (MAPKs), and a subsequent increase in the production and exocytosis of BDNF from microglia [13].

Dimethyl fumarate (DMF) has already been approved for multiple sclerosis. It acts by targeting Nrf2, increasing the transcription of antioxidant genes such as HO-1, GSH, and NADPH [14,15]. Studies in Nrf2-knockout mice revealed that Nrf2 is required to disseminate the therapeutic potential of fumarates [16]. An inhibitory effect of DMF has also been found on p38 MAPK, which is a crucial step in producing and releasing BDNF in the dorsal horn of the spinal cord.

Additionally, the activation of p38 MAPK in neuroinflammation leads to the release of pro-inflammatory cytokines such as interleukin (IL)-1β, IL-6, and tumor necrosis factor-alpha (TNF-α). This pathway further leads to the inactivation of Nrf2 and leads to a decrease in antioxidant gene transcription. Therefore, mitogen-activated protein kinase (MAPK) inhibition results in reduced inflammation. It stimulates antioxidant mechanisms by activating Nrf2 and reducing central sensitization [14,17]. This study was conducted to understand the effect of DMF in paclitaxel (PTX)-induced peripheral neuropathy through the activation of Nrf2 and the inhibition of p38 MAPK and BDNF in rats.

Materials & Methods

Animals

Thirty male Wistar rats weighing 200-250 g were used in this study. The animals were kept in a 12-hour light/dark cycle with a temperature of 23°C ± 2°C and relative humidity of 65%. Rats had ad libitum access to a standard pellet chow diet and tap water. The experiments were carried out according to the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA) guidelines for using animals in research. The experimental procedures were approved by the Institutional Animal Ethics Committee (#IAEC/AIIMS/RISH/PHAR/01/19). A minimum possible number of rats was utilized in the experiment.

Study design

The animals were divided into five groups, and different drugs were given in all the groups as in Table 1.

Experimental group Drugs and vehicle
Vehicle control CMC 0.5%
PTX Paclitaxel 2 mg/kg + CMC 0.5%
PTX + GBP Paclitaxel 2 mg/kg + gabapentin 70 mg/kg
PTX + DMF 25 Paclitaxel 2 mg/kg + dimethyl fumarate 25 mg/kg
PTX + DMF 50 Paclitaxel 2 mg/kg + dimethyl fumarate 50 mg/kg

Drugs and chemicals

Paclitaxel (Sisco Research Laboratories (SRL) Pvt. Ltd., India) dissolved in CMC 0.5% was administered every alternate day for one week. Dimethyl fumarate (Sigma Aldrich, USA) dissolved in 0.5% carboxymethyl cellulose (CMC) was given orally (p.o.) for one week. Likewise, gabapentin (75 mg/kg) dissolved in 0.9% saline was given orally (p.o.) for one week. The treatment of gabapentin and dimethyl fumarate was given daily from day 0 to day 6. Enzyme-linked immunosorbent assay (ELISA) kits for interleukin (IL)-1β, IL-6, and tumor necrosis factor-alpha (TNF-α) were purchased from Invitrogen, USA. ELISA kit for the estimation of p38 MAPK was purchased from G Biosciences, USA.

Induction of peripheral neuropathy

Peripheral neuropathy was induced in animals by administering intraperitoneal (i.p.) injection of paclitaxel (PTX) 2 mg/kg on days 0, 2, 4, and 6. The assessment of pain threshold was done before administering PTX on day 0 and after administering PTX on days 7, 14, 21, and 28.

Assessment of thermal hyperalgesia

The instrument used in our study was Eddy’s Hot Plate Analgesio Meter (INCO Scientific, India). It consists of an electrically heated flat platform from which the animal cannot escape by itself. In this experiment, the hot plate was kept at 52°C-55°C. The individual rats were placed on the hot plate, and minimum threshold time was considered as soon as responses such as jumping or licking of the paws were seen. The maximum interval to last on the hot plate was 20 seconds to avoid any tissue injury. Eddy’s hot plate test was performed on days 0, 7, 14, 21, and 28 [18].

Assessment of mechanical allodynia

Before administering PTX, baseline readings for mechanical sensitivity were measured on day 0, and subsequent measurements were taken on days 7, 14, 21, and 28. The mechanical paw withdrawal threshold was evaluated using the von Frey aesthesiometer (Ugo Basile, Italy) on the left hind paw of the rats [19,20]. The minimum pressure that triggers the paw withdrawal was considered the mechanical withdrawal threshold. A series of stimulants with different weights were applied thrice with a five-minute interval in each measurement. The final reading was the mean of three observations for each rat [20].

Assessment of cold allodynia

The tail immersion test was used to assess cold allodynia. A beaker filled with ice-cold water was used to assess cold allodynia in rats. The water temperature was kept at 4°C, and the tip of the rat tail was dipped into that water. The latency to flick the tail was recorded. The maximum cutoff was kept at 20 seconds to avoid any tissue damage [21].

Enzyme-linked immunosorbent assay (ELISA)

The sciatic nerve and dorsal horns of spinal cord tissues were collected on day 28 and stored at -80°C. Specific kits were used to record the concentration of p38 MAPK (G Biosciences, USA) and BDNF (Invitrogen, USA) in the spinal cord dorsal horn. For pro-inflammatory cytokines (IL-6, IL-1β, and TNF-α), specific kits (Invitrogen, USA) were used to measure the concentration of each in the sciatic nerve. Experiments were conducted as per the manufacturers’ instructions in the respective kits.

Preparation of sciatic nerve tissues and staining techniques

Sciatic nerves were collected by sacrificing animals with a high dose of ketamine and xylazine solutions. A small portion of the sciatic nerve (1 cm) was isolated for histopathological examination. Samples were fixed in a 10% buffered formaldehyde solution. An automated tissue processor (Leica Biosystems, Nußloch, Germany) was used to process the tissues fixed in formaldehyde. Each sample was embedded in the paraffin wax block. Tissue samples in these blocks were cut into 5-6 µm each section. These sections were stained with hematoxylin and eosin (H&E), and Luxol fast blue (LFB) staining was performed. The sciatic nerves were examined under a light microscope. The ImageJ program (Bethesda, MD, USA) was used to measure the thickness of axons and calculate their number in a 2,500 µm2 area. For assessing the intact structure, the myelin in the sciatic nerve LFB stain was observed under a light microscope.

Quantitative polymerase chain reaction (qPCR)

Real-time polymerase chain reaction (RT-PCR) was used to analyze the gene expression of Nrf2 and β-actin (housekeeping gene). On day 28, the animals were sacrificed with an overdose of an anesthetic agent, and sciatic nerves were harvested. The total RNA was isolated with TRIzol (Invitrogen, USA) as per the manufacturer’s instructions. The quality and quantity of the total RNA isolated were assured by NanoQuant Plate™ using Tecan Infinite F200 Pro Microplate Reader (Tecan, Switzerland). GoTaq® 2-Step RT-qPCR System (Promega, USA) was used for gene expression. cDNA was synthesized from the isolated mRNA using GoScript™ Reverse Transcriptase. RT-PCR (quantitative) was carried out using the GoTaq® qPCR Master Mix (Promega, USA) in Rotor-Gene Q (Qiagen, Germany) machine. The cycle threshold (CT) value of each sample was noted. Fold change in different groups was calculated using the 2−ΔΔCT method [19].

Statistical analysis

The data obtained are expressed as mean ± standard error of the mean (SEM). Two-way analysis of variance (ANOVA) followed by a post hoc Tukey test was used to test the difference at different time points within the group in the case of behavioral studies such as hot plate, tail immersion, and von Frey tests. One-way ANOVA followed by a post hoc Tukey test was used to statistically compare pro-inflammatory cytokines, p38 MAPK, BDNF, axon thickness, number of axons, and mRNA levels between the experimental groups. All tests were performed using GraphPad Prism 8.4.3.686 software (San Diego, California, USA).

Results

Effect of dimethyl fumarate (DMF) on thermal hyperalgesia

The PTX treatment significantly decreased the escape latency from Eddy’s hot plate on day 7 (7.77 ± 0.76), day 14 (7.44 ± 0.26), day 21 (7.50 ± 0.41), and day 28 (7.77 ± 0.31) compared to baseline latency (15.38 ± 0.92) (Table 2), which indicates that PTX-administered animals developed thermal hyperalgesia. In contrast, the coadministration of DMF 25 mg/kg and DMF 50 mg/kg significantly attenuated PTX-induced thermal hyperalgesia, which indicates the protective effect of DMF. The escape latency did not decline significantly from day 7 (13.33 ± 0.58) to day 28 (14.83 ± 0.54) as compared to day 0 (16.11 ± 0.36) (Table 2). In GBP-treated animals, the improvement in latency time started from day 14 onward because a significant increase in escape latency was observed.

  Vehicle control (CMC 0.5%) PTX (2 mg/kg) + CMC 0.5% PTX + gabapentin 75 mg/kg PTX + dimethyl fumarate 25 mg/kg PTX + dimethyl fumarate 50 mg/kg
Day 0 15.16 ± 1.13 15.38 ± 0.92 16.11 ± 0.36 16.11 ± 0.36 14.22 ± 0.93
Day 7 12.10 ± 0.70* 07.77 ± 0.76**## 10.83 ± 0.41**† 13.33 ± 0.58†† 13.66 ± 1.7††
Day 14 13.83 ± 0.54 07.44 ± 0.26**## 13.11 ± 0.32*†† 13.83 ± 0.76†† 15.11 ± 1.13††
Day 21 13.83 ± 0.30 07.50 ± 0.41**## 14.55 ± 0.34†† 14.67 ± 0.76†† 16.22 ± 1.03††
Day 28 12.84 ± 0.30 07.77 ± 0.31**## 14.55 ± 0.34†† 14.83 ± 0.54†† 15.00 ± 0.60††

Effect of DMF on tail cold allodynia

Table 3 represents the effect of DMF and GBP on cold allodynia. Animals administered with PTX experienced a reduction in the latency on day 14 (7.66 ± 0.66) and day 28 (8.66 ± 0.88) in comparison to day 0, which was statistically significant (Table 3). This decline in the latency time indicates that PTX-treated animals developed cold allodynia. However, the coadministration of GBP (75 mg/kg), DMF (25 mg/kg), and DMF (50 mg/kg) significantly improved PTX-induced cold allodynia, and this implies protection by GBP and DMF.

  Vehicle control (CMC 0.5%) PTX (2 mg/kg) + CMC 0.5% PTX + gabapentin 75 mg/kg PTX + dimethyl fumarate 25 mg/kg PTX + dimethyl fumarate 50 mg/kg
Day 0 12.50 ± 0.80 12.83 ± 0.60 11.66 ± 0.66 13.16 ± 0.87 12.00 ± 0.77
Day 7 11.50 ± 0.56 09.50 ± 0.99 11.66 ± 0.71 11.16 ± 0.83 10.66 ± 0.76
Day 14 12.66 ± 0.33 07.66 ± 0.66**# 08.50 ± 1.23 10.16 ± 0.87 11.50 ± 0.61
Day 21 13.16 ± 1.35 09.33 ± 0.80# 09.83 ± 1.10 11.66 ± 1.28 13.33 ± 1.08
Day 28 12.83 ± 0.83 08.66 ± 0.88*# 11.16 ± 1.13 11.83 ± 1.24 13.83 ± 0.83

Effect of DMF on mechanical allodynia

Paclitaxel (2 mg/kg) significantly shortened the paw withdrawal threshold on day 7 (20.5 ± 2.45 g), day 21 (18.66 ± 2.31 g), and day 28 (15.16 ± 0.16 g) as compared to the baseline readings on day 0 (43 ± 7.6 g). Nonetheless, GBP and DMF significantly delayed the paw withdrawal when coadministered with PTX (Table 4).

  Vehicle control (CMC 0.5%) PTX (2 mg/kg) + CMC 0.5% PTX + gabapentin 75 mg/kg PTX + dimethyl fumarate 25 mg/kg PTX + dimethyl fumarate 50 mg/kg
Day 0 52.50 ± 7.50 43.00 ± 7.60 37.33 ± 7.16 66.66 ± 6.66 60.00 ± 00.00
Day 7 54.33 ± 5.66 20.50 ± 2.45*## 41.16 ± 8.58 41.16 ± 8.58 53.50 ± 12.28
Day 14 48.66 ± 7.16 20.50 ± 2.45*# 43.00 ± 7.60 54.33 ± 5.66 60.00 ± 00.00
Day 21 61.00 ± 9.57 18.66 ± 2.31*## 48.66 ± 7.16 54.33 ± 5.66 54.33 ± 05.66
Day 28 48.66 ± 7.16 15.16 ± 0.16*## 48.66 ± 7.16 54.33 ± 5.66 54.33 ± 05.66

Effect of DMF on pro-inflammatory cytokines

The results revealed that IL-6 and IL-1β were significantly elevated in the paclitaxel group. DMF and GBP significantly blunted the effect of PTX on the levels of PTX IL-6 and IL-1β (Figure 1). Nonetheless, TNF-α did not significantly change in PTX-treated animals as compared to the control group (Figure 1).

Effect of DMF on BDNF and p38 MAPK

The levels of p38 MAPK and BDNF in the dorsal horn of the spinal cord are presented in Figure 2. The study revealed that paclitaxel treatment increased the expression of p38 MAPK and BDNF compared to the control group. However, DMF and GBP attenuated the paclitaxel-induced increase in p38 MAPK and BDNF levels in the spinal cord’s dorsal horns.

Effect of DMF on the gene expression of Nrf2/β-actin

The relative gene expression of Nrf2 in the sciatic nerve of rats of various groups is shown in Figure 3. PTX did not significantly change the expression of Nrf2 as compared to the vehicle control group. Also, no significant change in the GBP + PTX group was seen. However, DMF 50 mg/kg treatment significantly increased the expression of Nrf2 in the paclitaxel-treated rats.

Effect of DMF on histopathological changes

The axonal diameter in the animals treated with PTX 2 mg/kg + CMC 0.5% was reduced, and that reduction was statistically significant in comparison to the vehicle control group (Figure 4 and Figure 5). On the other hand, a statistically significant increase in the diameter was observed in the PTX 2 mg/kg + GBP 5 mg/kg treatment group in comparison to the PTX 2 mg/kg + CMC 0.5% treatment group. Likewise, in paclitaxel 2 mg/kg + dimethyl fumarate 25 mg/kg animals, the axonal diameter was comparatively high as compared to the animals treated with PTX 2 mg/kg + CMC 0.5%. Also, in paclitaxel 2 mg/kg + dimethyl fumarate 50 mg/kg animals, the axonal diameter was greater than in the group treated with PTX 2 mg/kg + CMC 0.5%. The change in both the DMF-treated groups was statistically significant.

Discussion

Chemotherapy-induced peripheral neuropathy is an utmost side effect encountered through several drugs used to treat cancer. Although each drug has a different mechanism of action in cancer, they all produce oxidative stress, the main contributor to peripheral neuropathy. Likewise, the microtubule stabilizer paclitaxel results in peripheral neuropathy (PIPN). Currently, 7%-10% of the global population suffers from peripheral neuropathy [2,3,22].

In this study, paclitaxel treatment (2 mg/kg injection on days 0, 2, 4, and 6) caused neuropathy manifesting in the form of thermal hyperalgesia, mechanical allodynia, and tail cold allodynia. The same has already been reported in previous studies with different doses of paclitaxel in different animal models [1,7,23-25]. GBP prevented the development of PTX-induced thermal hyperalgesia, mechanical allodynia, and tail cold allodynia in the rats. The protective effects of GBP in PTX-induced neuropathy have already been reported in clinical and nonclinical studies [26-28]. DMF (25 mg/kg and 50 mg/kg) effectively ameliorated the thermal hyperalgesia, mechanical allodynia, and tail cold allodynia induced by PTX. Likewise, past studies observed a similar effect of DMF in other models of chemotherapy-induced peripheral neuropathy [29-31].

Recent research has shown central sensitization’s role in worsening neuropathic pain [8,32]. Microglial cells in the spinal cord dorsal horn play a substantial role in the induction of central sensitization [33]. BDNF is a neuropeptide that has been reported to exacerbate central sensitization [34-36]. The release of BDNF increases from microglial cells in the dorsal horn of the spinal cord whenever there is a peripheral nerve injury mediated by the increased expression of the ATP-gated ionotropic purinoceptor 2X4 (P2X4R); this increase in expression parallels the increase in pain hypersensitivity [2]. The BDNF released from microglia is dependent on the influx of Ca2+via P2X4Rs, which activates p38 MAPK, resulting in the increased production and release of BDNF [13].

As reported by previous mechanistic studies to link BDNF and p38 MAPK, BDNF and p38 MAPK levels in the spinal cord dorsal horn of neuropathic rats in the paclitaxel group were significantly high as compared to the control group [12,37,38]. Nevertheless, DMF treatment significantly attenuated the effect of paclitaxel on p38 MAPK and BDNF. Decreased BDNF levels could be the effect of p38 MAPK inhibition by DMF, which is already known [17,39]. The inhibition of the phosphorylation of p38 MAPK can further inhibit the production and exocytosis of BDNF in the spinal cord dorsal horn [12].

IL-1β, IL-6, and TNF-α pro-inflammatory cytokines are factors responsible for neuroinflammation in peripheral and central neuropathy. Other than axonal damage, pro-inflammatory cytokines change spontaneous nociception and stimulus sensitivity. In the sensory neurons, p38 MAPK and Jun-N-terminal kinase (JNK) phosphorylation is initiated by the activation of TNF receptors and the hiring of TNF receptor-associated factors (TRAFs), which possibly activates nuclear factor-kappa B (NF-kB) [40].

Paclitaxel and other chemotherapeutic agents cause many histopathological changes in the peripheral nerves. Therefore, we examined the histopathology of the sciatic nerve in peripheral neuropathy and the effect of DMF treatments. The PTX treatment significantly reduced the number of axons and the axonal diameter in the sciatic nerve. A recent study has also reported the same in PINP [7]. The gabapentin treatment group, compared to the PTX group, significantly retained the axonal diameter and the number of axons per 2,500-micrometer area. Likewise, DMF also preserved the number of axons and the axonal diameter in the DMF-treated groups. Our results were similar to the previous studies, where GBP and DMF have been reported to be neuroprotective [41,42].

This is an established fact that DMF acts by the activation of Nrf2; as a result, it increases the expression of antioxidant proteins. Nrf2 expression in the PTX- and GBP-treated group was not changed. In the DMF 50 mg/kg treatment group, however, a significant increase in the Nrf2 expression was seen. These findings were parallel to the previously reported evidence of DMF in neurological disorders [15,16,43].

In the neuropathic rats treated with paclitaxel in this study, IL-1β and IL-6 levels significantly increased. On the other hand, significant protection against the paclitaxel-induced rise in IL-1β and IL-6 was demonstrated by DMF and GBP. This effect could be because of the p38 MAPK activation inhibition property of DMF and GBP, which is a crucial step in the production of intracellular pro-inflammatory cytokines [17,44-46].

It is a known fact that DMF shows neuroprotection by activating the Nrf2 cascade of antioxidant proteins. In the Nrf2 knockout mouse, the DMF showed minimal or no effect [15,16,43]. In the present study, we examined whether paclitaxel-induced peripheral neuropathy is ameliorated by activating the Nrf2 gene in rats administered with DMF.

Conclusions

The study demonstrated that DMF shows significant protection against paclitaxel-induced peripheral neuropathy in rats. The reduction in pro-inflammatory cytokines and increases in the Nrf2 gene expression suggest that DMF curbed inflammation and increased antioxidant defense. Furthermore, the reduced p38 MAPK and BDNF in the dorsal horn of the spinal cord indicate that DMF might be acting by decreasing the central sensitization of neuropathic pain.


References

  1. Velasco R, Bruna J: Taxane-induced peripheral neurotoxicity. Toxics. 2015, 3:152-69. 10.3390/toxics3020152
  2. Bouhassira D, Lantéri-Minet M, Attal N, Laurent B, Touboul C: Prevalence of chronic pain with neuropathic characteristics in the general population. Pain. 2008, 136:380-7. 10.1016/j.pain.2007.08.013
  3. Torrance N, Ferguson JA, Afolabi E, Bennett MI, Serpell MG, Dunn KM, Smith BH: Neuropathic pain in the community: more under-treated than refractory?. Pain. 2013, 154:690-9. 10.1016/j.pain.2012.12.022
  4. Seretny M, Currie GL, Sena ES, et al.: Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain. 2014, 155:2461-70. 10.1016/j.pain.2014.09.020
  5. Han Y, Smith MT: Pathobiology of cancer chemotherapy-induced peripheral neuropathy (CIPN). Front Pharmacol. 2013, 4:156. 10.3389/fphar.2013.00156
  6. Areti A, Yerra VG, Naidu V, Kumar A: Oxidative stress and nerve damage: role in chemotherapy induced peripheral neuropathy. Redox Biol. 2014, 2:289-95. 10.1016/j.redox.2014.01.006
  7. Singh J, Saha L, Singh N, Kumari P, Bhatia A, Chakrabarti A: Study of nuclear factor-2 erythroid related factor-2 activator, berberine, in paclitaxel induced peripheral neuropathy pain model in rats. J Pharm Pharmacol. 2019, 71:797-805. 10.1111/jphp.13047
  8. Latremoliere A, Woolf CJ: Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J Pain. 2009, 10:895-926. 10.1016/j.jpain.2009.06.012
  9. Yuan X, Wang J, Tang X, Li Y, Xia P, Gao X: Berberine ameliorates nonalcoholic fatty liver disease by a global modulation of hepatic mRNA and lncRNA expression profiles. J Transl Med. 2015, 13:24. 10.1186/s12967-015-0383-6
  10. Zhao J, Kobori N, Aronowski J, Dash PK: Sulforaphane reduces infarct volume following focal cerebral ischemia in rodents. Neurosci Lett. 2006, 393:108-12. 10.1016/j.neulet.2005.09.065
  11. Saha S, Buttari B, Panieri E, Profumo E, Saso L: An overview of Nrf2 signaling pathway and its role in inflammation. Molecules. 2020, 25:10.3390/molecules25225474
  12. Trang T, Beggs S, Wan X, Salter MW: P2X4-receptor-mediated synthesis and release of brain-derived neurotrophic factor in microglia is dependent on calcium and p38-mitogen-activated protein kinase activation. J Neurosci. 2009, 29:3518-28. 10.1523/JNEUROSCI.5714-08.2009
  13. Alles SR, Smith PA: Etiology and pharmacology of neuropathic pain. Pharmacol Rev. 2018, 70:315-47. 10.1124/pr.117.014399
  14. Wang Q, Chuikov S, Taitano S, et al.: Dimethyl fumarate protects neural stem/progenitor cells and neurons from oxidative damage through Nrf2-ERK1/2 MAPK pathway. Int J Mol Sci. 2015, 16:13885-907. 10.3390/ijms160613885
  15. McGuire VA, Ruiz-Zorrilla Diez T, Emmerich CH, et al.: Dimethyl fumarate blocks pro-inflammatory cytokine production via inhibition of TLR induced M1 and K63 ubiquitin chain formation. Sci Rep. 2016, 6:31159. 10.1038/srep31159
  16. Lastres-Becker I, García-Yagüe AJ, Scannevin RH, Casarejos MJ, Kügler S, Rábano A, Cuadrado A: Repurposing the Nrf2 activator dimethyl fumarate as therapy against synucleinopathy in Parkinson’s disease. Antioxid Redox Signal. 2016, 25:61-77. 10.1089/ars.2015.6549
  17. Gesser B, Johansen C, Rasmussen MK, et al.: Dimethylfumarate specifically inhibits the mitogen and stress-activated kinases 1 and 2 (MSK1/2): possible role for its anti-psoriatic effect. J Invest Dermatol. 2007, 127:2129-37. 10.1038/sj.jid.5700859
  18. Eddy NB, Leimbach D: Synthetic analgesics. II. Dithienylbutenyl- and dithienylbutylamines. J Pharmacol Exp Ther. 1953, 107:385-93.
  19. Kalynovska N, Diallo M, Sotakova-Kasparova D, Palecek J: Losartan attenuates neuroinflammation and neuropathic pain in paclitaxel-induced peripheral neuropathy. J Cell Mol Med. 2020, 24:7949-58. 10.1111/jcmm.15427
  20. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL: Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods. 1994, 53:55-63. 10.1016/0165-0270(94)90144-9
  21. Na HS, Han JS, Ko KH, Hong SK: A behavioral model for peripheral neuropathy produced in rat's tail by inferior caudal trunk injury. Neurosci Lett. 1994, 177:50-2. 10.1016/0304-3940(94)90042-6
  22. Basu P, Averitt DL, Maier C, Basu A: The effects of nuclear factor erythroid 2 (NFE2)-related factor 2 (Nrf2) activation in preclinical models of peripheral neuropathic pain. Antioxidants (Basel). 2022, 11:10.3390/antiox11020430
  23. Polomano RC, Mannes AJ, Clark US, Bennett GJ: A painful peripheral neuropathy in the rat produced by the chemotherapeutic drug, paclitaxel. Pain. 2001, 94:293-304. 10.1016/S0304-3959(01)00363-3
  24. Jaggi AS, Jain V, Singh N: Animal models of neuropathic pain. Fundam Clin Pharmacol. 2011, 25:1-28. 10.1111/j.1472-8206.2009.00801.x
  25. Yardım A, Kandemir FM, Çomaklı S, Özdemir S, Caglayan C, Kucukler S, Çelik H: Protective effects of curcumin against paclitaxel-induced spinal cord and sciatic nerve injuries in rats. Neurochem Res. 2021, 46:379-95. 10.1007/s11064-020-03174-0
  26. Aghili M, Zare M, Mousavi N, et al.: Efficacy of gabapentin for the prevention of paclitaxel induced peripheral neuropathy: a randomized placebo controlled clinical trial. Breast J. 2019, 25:226-31. 10.1111/tbj.13196
  27. Kato N, Tateishi K, Tsubaki M, et al.: Gabapentin and duloxetine prevent oxaliplatin- and paclitaxel-induced peripheral neuropathy by inhibiting extracellular signal-regulated kinase 1/2 (ERK1/2) phosphorylation in spinal cords of mice. Pharmaceuticals (Basel). 2020, 14:10.3390/ph14010030
  28. Mangaiarkkarasi A, Rameshkannan S, Ali RM: Effect of gabapentin and pregabalin in rat model of Taxol induced neuropathic pain. J Clin Diagn Res. 2015, 9:FF11-4. 10.7860/JCDR/2015/13373.5955
  29. Miyagi A, Kawashiri T, Shimizu S, Shigematsu N, Kobayashi D, Shimazoe T: Dimethyl fumarate attenuates oxaliplatin-induced peripheral neuropathy without affecting the anti-tumor activity of oxaliplatin in rodents. Biol Pharm Bull. 2019, 42:638-44. 10.1248/bpb.b18-00855
  30. Yamamoto S, Egashira N: Drug repositioning for the prevention and treatment of chemotherapy-induced peripheral neuropathy: a mechanism- and screening-based strategy. Front Pharmacol. 2020, 11:607780. 10.3389/fphar.2020.607780
  31. Pitarokoili K, Ambrosius B, Meyer D, Schrewe L, Gold R: Dimethyl fumarate ameliorates Lewis rat experimental autoimmune neuritis and mediates axonal protection. PLoS One. 2015, 10:e0143416. 10.1371/journal.pone.0143416
  32. Woolf CJ: Central sensitization: implications for the diagnosis and treatment of pain. Pain. 2011, 152:S2-S15. 10.1016/j.pain.2010.09.030
  33. Ikeda H, Kiritoshi T, Murase K: Contribution of microglia and astrocytes to the central sensitization, inflammatory and neuropathic pain in the juvenile rat. Mol Pain. 2012, 8:43. 10.1186/1744-8069-8-43
  34. Retamal J, Reyes A, Ramirez P, et al.: Burst-like subcutaneous electrical stimulation induces BDNF-mediated, cyclotraxin B-sensitive central sensitization in rat spinal cord. Front Pharmacol. 2018, 9:1143. 10.3389/fphar.2018.01143
  35. Zhou W, Xie Z, Li C, Xing Z, Xie S, Li M, Yao J: Driving effect of BDNF in the spinal dorsal horn on neuropathic pain. Neurosci Lett. 2021, 756:135965. 10.1016/j.neulet.2021.135965
  36. Shapoval I, Zaichko K, Stanislavchuk M: Pos0414 increased BDNF levels as a predictor of central sensitization in patients with ankylosing spondylitis. Ann Rheum Dis. 2021, 80:436-2. 10.1136/annrheumdis-2021-eular.3908
  37. Long T, He W, Pan Q, et al.: Microglia P2X4R-BDNF signalling contributes to central sensitization in a recurrent nitroglycerin-induced chronic migraine model. J Headache Pain. 2020, 21:4. 10.1186/s10194-019-1070-4
  38. Coull JA, Beggs S, Boudreau D, et al.: BDNF from microglia causes the shift in neuronal anion gradient underlying neuropathic pain. Nature. 2005, 438:1017-21. 10.1038/nature04223
  39. Nishioku T, Kawamoto M, Okizono R, Sakai E, Okamoto K, Tsukuba T: Dimethyl fumarate prevents osteoclastogenesis by decreasing NFATc1 expression, inhibiting of erk and p38 MAPK phosphorylation, and suppressing of HMGB1 release. Biochem Biophys Res Commun. 2020, 530:455-61. 10.1016/j.bbrc.2020.05.088
  40. Scholz J, Woolf CJ: The neuropathic pain triad: neurons, immune cells and glia. Nat Neurosci. 2007, 10:1361-8. 10.1038/nn1992
  41. Krämer T, Grob T, Menzel L, et al.: Dimethyl fumarate treatment after traumatic brain injury prevents depletion of antioxidative brain glutathione and confers neuroprotection. J Neurochem. 2017, 143:523-33. 10.1111/jnc.14220
  42. Wilms H, Sievers J, Rickert U, Rostami-Yazdi M, Mrowietz U, Lucius R: Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1beta, TNF-alpha and IL-6 in an in-vitro model of brain inflammation. J Neuroinflammation. 2010, 7:30. 10.1186/1742-2094-7-30
  43. Lal R, Dhaliwal J, Dhaliwal N, Dharavath RN, Chopra K: Activation of the Nrf2/HO-1 signaling pathway by dimethyl fumarate ameliorates complete Freund's adjuvant-induced arthritis in rats. Eur J Pharmacol. 2021, 899:174044. 10.1016/j.ejphar.2021.174044
  44. Yeung YT, Bryce NS, Adams S, et al.: p38 MAPK inhibitors attenuate pro-inflammatory cytokine production and the invasiveness of human U251 glioblastoma cells. J Neurooncol. 2012, 109:35-44. 10.1007/s11060-012-0875-7
  45. Zhao YW, Pan YQ, Tang MM, Lin WJ: Blocking p38 signaling reduces the activation of pro-inflammatory cytokines and the phosphorylation of p38 in the habenula and reverses depressive-like behaviors induced by neuroinflammation. Front Pharmacol. 2018, 9:511. 10.3389/fphar.2018.00511
  46. Bachstetter AD, Xing B, de Almeida L, Dimayuga ER, Watterson DM, Van Eldik LJ: Microglial p38α MAPK is a key regulator of proinflammatory cytokine up-regulation induced by toll-like receptor (TLR) ligands or beta-amyloid (Aβ). J Neuroinflammation. 2011, 8:79. 10.1186/1742-2094-8-79

Original article
peer-reviewed

Dimethyl Fumarate Ameliorates Paclitaxel-Induced Neuropathic Pain in Rats


Author Information

Jagjit Singh

Department of Pharmacology, All India Institute of Medical Sciences, Rishikesh, Rishikesh, IND

Surabhi Thapliyal

Department of Pharmacology, All India Institute of Medical Sciences, Rishikesh, Rishikesh, IND

Ashish Kumar

Department of Biochemistry, All India Institute of Medical Sciences, Rishikesh, Rishikesh, IND

Pranoy Paul

Department of Pathology, All India Institute of Medical Sciences, Rishikesh, Rishikesh, IND

Nitesh Kumar

Department of Biochemistry, All India Institute of Medical Sciences, Rishikesh, Rishikesh, IND

Manisha Bisht

Department of Pharmacology, All India Institute of Medical Sciences, Rishikesh, Rishikesh, IND

Manisha Naithani

Department of Biochemistry, All India Institute of Medical Sciences, Rishikesh, Rishikesh, IND

Shalinee Rao

Department of Pathology, All India Institute of Medical Sciences, Rishikesh, Rishikesh, IND

Shailendra S. Handu Corresponding Author

Department of Pharmacology, All India Institute of Medical Sciences, Rishikesh, Rishikesh, IND


Ethics Statement and Conflict of Interest Disclosures

Human subjects: All authors have confirmed that this study did not involve human participants or tissue. Animal subjects: The Institutional Animal Ethics Committee (IAEC), All India Institute of Medical Sciences (AIIMS), Rishikesh (registration number 2070/GO/ReBi/S/1 9/CPCSEA) Issued protocol number IAEC/AIIMS/RISH/PHAR/01/19. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: This research was funded by the Indian Council of Medical Research (ICMR), New Delhi (reference number 58/9/2019-BMS/PHA). Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Acknowledgements

This research was funded by the Indian Council of Medical Research (ICMR), New Delhi (reference number 58/9/2019-BMS/PHA).



Original article
peer-reviewed

Dimethyl Fumarate Ameliorates Paclitaxel-Induced Neuropathic Pain in Rats


Figures etc.

SIQ
-
RATED BY 0 READERS
CONTRIBUTE RATING

Scholarly Impact Quotient™ (SIQ™) is our unique post-publication peer review rating process. Learn more here.